This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Responses, Treatment-Related Morbidity, and Histologic Findings

Michael T. Lotze, MD; Alfred E. Chang, MD; Claudia A. Seipp, RN; Colleen Simpson, RN; John T. Vetto, MD; Steven A. Rosenberg, MD, PhD

JAMA. 1986;256(22):3117-3124.

Abstract
Experience with the administration of high doses of interleukin 2 (IL-2) alone is described herein. Ten patients with a variety of malignant disorders unresponsive to conventional treatments were treated with at least 30 000 U/kg of IL-2 by bolus administration three times a day. Patients were treated intravenously or intraperitoneally from four to 21 days in a single course, usually interrupted by a week of recovery. Three of six patients with melanoma experienced an objective regression (>50% decrease in volume); there was no response to treatment in patients with colorectal (0/3) or ovarian (0/1) cancer. Two patients with initial objective regressions who subsequently developed progression were re-treated and one sustained a second partial response. Responses lasted 1, 3, and 7 months without additional treatment. Responses in the three patients with melanoma were in visceral sites (lung, liver, and spleen), as well as cutaneous sites in one patient. Progressive shrinkage of tumors for three to six months after the conclusion of therapy has been noted in two patients. Marked lymphocytic infiltrate was noted in a patient with lesions accessible to repeated biopsies. This study demonstrates that the administration of IL-2 can mediate the regression of established cancer in some patients.

(JAMA 1986;256:3117-3124)

Author Affiliations
From the Surgery Branch, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, Md.

Footnotes
Read in part before the Eastern Cooperative Oncology Group Meeting, Clearwater Beach, Fla, Nov 22, 1985.

Reprint requests to Surgery Branch, National Cancer Institute, Bldg 10, Room 2B56, Bethesda, MD 20892 (Dr Lotze).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

IL-2 and IL-18 Attenuation of Airway Hyperresponsiveness Requires STAT4, IFN-{gamma}, and Natural Killer Cells
Matsubara et al.
Am. J. Respir. Cell Mol. Bio. 2007;36:324-332.
ABSTRACT | FULL TEXT  

Limited Capability of Regional Lymph Nodes to Eradicate Metastatic Cancer Cells
Nagata et al.
Cancer Res. 2004;64:8239-8248.
ABSTRACT | FULL TEXT  

Failed Adoptive Immunotherapy with Tumor-Specific T Cells: Reversal with Low-Dose Interleukin 15 but not Low-Dose Interleukin 2
Roychowdhury et al.
Cancer Res. 2004;64:8062-8067.
ABSTRACT | FULL TEXT  

Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer
Yang et al.
JCO 2003;21:3127-3132.
ABSTRACT | FULL TEXT  

Factors Associated With Response to High-Dose Interleukin-2 in Patients With Metastatic Melanoma
Phan et al.
JCO 2001;19:3477-3482.
ABSTRACT | FULL TEXT  

Enhancement of Tumor Lysate- and Peptide-pulsed Dendritic Cell-based Vaccines by the Addition of Foreign Helper Protein
Shimizu et al.
Cancer Res. 2001;61:2618-2624.
ABSTRACT | FULL TEXT  

Interleukin-18 (IL-18) Synergizes with IL-2 to Enhance Cytotoxicity, Interferon-{{gamma}} Production, and Expansion of Natural Killer Cells
Son et al.
Cancer Res. 2001;61:884-888.
ABSTRACT | FULL TEXT  

Impact of the Number of Treatment Courses on the Clinical Response of Patients Who Receive High-Dose Bolus Interleukin-2
Lindsey et al.
JCO 2000;18:1954-1959.
ABSTRACT | FULL TEXT  

Fractalkine-Mediated Endothelial Cell Injury by NK Cells
Yoneda et al.
J. Immunol. 2000;164:4055-4062.
ABSTRACT | FULL TEXT  

Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines
Shimizu et al.
Proc. Natl. Acad. Sci. USA 1999;96:2268-2273.
ABSTRACT | FULL TEXT  

Sarcomatoid Renal Cell Carcinoma: Biologic Behavior, Prognosis, and Response to Combined Surgical Resection and Immunotherapy
Cangiano et al.
JCO 1999;17:523-523.
ABSTRACT | FULL TEXT  

The tetravalent guanylhydrazone CNI-1493 blocks the toxic effects of interleukin-2 without diminishing antitumor efficacy
Kemeny et al.
Proc. Natl. Acad. Sci. USA 1998;95:4561-4566.
ABSTRACT | FULL TEXT  

Interleukin-la Reduces the Severity of the Vascular Leak Syndrome Produced by Interleukin-2 and Interleukin-2 Plus Interferon-a
Fujita et al.
Toxicol Pathol 1994;22:381-397.
ABSTRACT  

Autoimmunity as a Complication of Interleukin 2 Immunotherapy: Many Unanswered Questions
Gaspari
Arch Dermatol 1994;130:894-898.
ABSTRACT  

Treatment of 283 Consecutive Patients With Metastatic Melanoma or Renal Cell Cancer Using High-Dose Bolus Interleukin 2
Rosenberg et al.
JAMA 1994;271:907-913.
ABSTRACT  

Immunotherapy for Metastatic Cancer: Establishing a 'Proof of Principle'
Hellman
JAMA 1994;271:945-946.
ABSTRACT  

Adoptive Cellular Therapy of Malignancy
Chang et al.
Arch Surg 1993;128:1281-1290.
ABSTRACT  

Acute-Phase Proteins in Patients With Head and Neck Cancer Treated With Interleukin 2/Interferon Alfa
Clayman et al.
Arch Otolaryngol Head Neck Surg 1992;118:41-48.
ABSTRACT  

Neuro-ophthalmic Complications of Interleukin 2 Therapy
Friedman et al.
Arch Ophthalmol 1991;109:1679-1680.
ABSTRACT  

Human Lymphokine-Activated Killer Cell Activity: Role of IL-2, IL-4, and IL-7
Stotter and Lotze
Arch Surg 1991;126:1525-1530.
ABSTRACT  

Treatment of Human Melanoma Hepatic Metastases in Nude Mice With Human Cytotoxic T Lymphocytes
Crowley et al.
Arch Surg 1991;126:433-437.
ABSTRACT  

Immune Dysfunctions and Activation of Natural Killer Cells in Human IL-2 and IL-2/IL-2 Receptor L-chain Transgenic Mice
Ishida et al.
Cold Spring Harb Symp Quant Biol 1989;54:695-704.
ABSTRACT  

Interleukin 2 and Psoriasis
Lee et al.
Arch Dermatol 1988;124:1811-1815.
ABSTRACT  

New Approaches to the Immunotherapy of Cancer Using Interleukin-2
ROSENBERG et al.
ANN INTERN MED 1988;108:853-864.
ABSTRACT  

Hepatocellular Carcinoma
DI BISCEGLIE et al.
ANN INTERN MED 1988;108:390-401.
ABSTRACT  

Marked Disparity in Incidence of Bacterial Infections in Patients with the Acquired Immunodeficiency Syndrome Receiving Interleukin-2 or Interferon-{gamma}
MURPHY et al.
ANN INTERN MED 1988;108:36-41.
ABSTRACT  

Erythema Nodosum in a Patient With Renal Cell Carcinoma Treated With Interleukin 2 and Lymphokine-Activated Killer Cells
Weinstein et al.
JAMA 1987;258:3120-3121.
ABSTRACT  

Interleukin 2 Therapy for Disseminated Cancer
Kradin and Kurnick
JAMA 1987;257:1729-1729.
ABSTRACT  

Interleukin 2 Therapy for Disseminated Cancer
Mittelman et al.
JAMA 1987;257:1729-1730.
ABSTRACT  

Interleukin 2 Therapy for Disseminated Cancer
Smith
JAMA 1987;257:1731-1731.
ABSTRACT  

Cancer M.D.'s clash over interleukin therapy
Bloom
Science 1987;235:154-155.
 

On Lymphokines, Cytokines, and Breakthroughs
Moertel
JAMA 1986;256:3141-3141.
ABSTRACT